Researchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren’s disease.
Based on their laboratory data that tumour necrosis factor (TNF) drives the development of myofibroblasts, the cell type that causes Dupuytren’s disease, the research team explored the effect of an anti-TNF drug injected directly into the Dupuytren’s nodule tissue. The results so far are very promising.
“Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren’s disease,” said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.
“This brings new hope to people who suffer from this disabling condition, who currently have to wait for their situation to be deteriorate, watching their hand lose function until it is bad enough for surgery. And then there’s the lengthy recovery ahead, a less than ideal situation to find yourself in.”
This randomised trial (phase 2a) recruited 28 patients with Dupuytren’s disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand. Two weeks prior to surgery they received a single injection of varying doses of the anti-TNF drug, or placebo. The tissue removed during surgery, which is usually discarded, was then analysed in the laboratory. The team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells. They also found the drug to be safe and well tolerated.
The findings are published on line in the journal EBioMedicine, published by The Lancet.
Dupuytren’s disease is a common condition of the hand that affects 4% of the UK population and causes the fingers to curl irreversibly into the palm. There is currently no NICE approved treatment for early disease and typically people are told to return to their GP once their fingers become so bent that their hand function is impaired.
The anti-TNF drug adalimumab (Humira) is currently licensed in the EU for the treatment of a number of conditions including rheumatoid arthritis, Crohn’s disease and ulcerative colitis and overall has an excellent safety profile.
“We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren’s disease,” said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute. In conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.
“The Kennedy Institute has a long history of successfully translating laboratory findings to the clinic'” said Professor Fiona Powrie, Director of the Institute. “This type of work requires close collaboration between laboratory scientists, clinical trialists and clinician scientists over many years”.
The researchers are continuing to investigate the use of this drug to treat Dupuytren’s disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.
The Latest on: Dupuytren’s disease
via Google News
The Latest on: Dupuytren’s disease
- Advances in Minimally Invasive Treatment of Hand Disorderson January 20, 2021 at 4:00 pm
New studies regarding less invasive treatment of Dupuytren’s disease and cubital tunnel syndrome (ulnar nerve entrapment at the elbow) have been reported in the past two years and have begun to ...
- How To Do Physiotherapy For Frozen Shoulder At Home? Know Tips From Experton January 20, 2021 at 10:13 am
Stroke, connective tissue disease, autoimmune disease, heart disease, and Dupuytren's contracture are other risk factors for frozen shoulder. In the development of a frozen shoulder, the ...
- Could tissue sparing surgery get rid of that pain in the neck?on January 20, 2021 at 8:52 am
Despite being one of the most common spinal surgeries, anterior cervical discectomy and fusion, a type of treatment for forms of degenerative disc disease, is a major procedure that sometimes fails in ...
- Understanding ED: Peyronie’s Diseaseon January 6, 2021 at 4:01 pm
Those with a connective tissue disorder called Dupuytren’s contracture have a higher chance of developing Peyronie’s disease. Dupuytren’s contracture is a thickening in the hand that makes ...
- Type 2 diabetes: Does your middle finger look or feel different? You could be at riskon January 6, 2021 at 11:23 am
Both conditions usually go undetected and can raise your risk of heart disease. However, as type diabetes progresses, it can spew out some sinister symptoms. Dupuytren’s contracture is a ...
- Dupuytren's Contracture Market Outlook (Covid19 Impact) 2020: Industry Demand, Size & Share and Analysis by Type, Application and End Useron December 29, 2020 at 4:11 pm
The exact causes of Dupuytren's contracture are unknown however the risk factors include alcoholism, smoking, thyroid problems, liver disease, diabetes, previous hand trauma, epilepsy, family ...
- It could be Dupuytren’s contractureon December 29, 2020 at 1:32 pm
XIAFLEX ® —an FDA-approved nonsurgical treatment for adults with Dupuytren’s contracture when a “cord” can be felt. Dupuytren’s contracture is a hand condition that may get worse over time.
- Crohn's Diseaseon December 18, 2020 at 3:51 am
Crohn's disease is a chronic inflammatory disease of the digestive system. Both Crohn's disease and ulcerative colitis are referred to as inflammatory bowel disease (IBD), not to be mistaken for ...
- Xiaflex Vialon August 13, 2020 at 9:29 pm
When used to treat a certain penis condition (Peyronie's disease), this drug has rarely ... do not have serious side effects. If treating Dupuytren's contracture, tell your doctor right away ...
via Bing News